Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 675

1.

Durable suppression of HIV-1 with resistance mutations to integrase inhibitors by dolutegravir following drug washout.

Osman N, Mesplède T, Oliveira M, Hassounah S, Wainberg MA, Brenner BG.

AIDS. 2018 Jun 11. doi: 10.1097/QAD.0000000000001903. [Epub ahead of print]

PMID:
29894388
2.

The S230R Integrase Substitution Associated with Viral Rebound during DTG Monotherapy Confers Low Levels INSTI Drug Resistance.

Pham HT, Labrie L, Wijting IEA, Hassounah S, Lok KY, Portna I, Goring M, Han Y, Lungu C, van der Ende ME, Brenner BG, Boucher CA, Rijnders BJA, van Kampen JJA, Mesplède T, Wainberg MA.

J Infect Dis. 2018 Mar 29. doi: 10.1093/infdis/jiy175. [Epub ahead of print]

PMID:
29617824
3.

Inhibition of NF-κB-dependent HIV-1 replication by the marine natural product bengamide A.

Tietjen I, Williams DE, Read S, Kuang XT, Mwimanzi P, Wilhelm E, Markle T, Kinloch NN, Naphen CN, Tenney K, Mesplède T, Wainberg MA, Crews P, Bell B, Andersen RJ, Brumme ZL, Brockman MA.

Antiviral Res. 2018 Apr;152:94-103. doi: 10.1016/j.antiviral.2018.02.017. Epub 2018 Feb 22.

PMID:
29476895
4.

The antimalarial drug amodiaquine possesses anti-ZIKA virus activities.

Han Y, Mesplède T, Xu H, Quan Y, Wainberg MA.

J Med Virol. 2018 May;90(5):796-802. doi: 10.1002/jmv.25031. Epub 2018 Feb 21.

PMID:
29315671
5.

Dolutegravir reshapes the genetic diversity of HIV-1 reservoirs.

Gantner P, Lee GQ, Rey D, Mesplede T, Partisani M, Cheneau C, Beck-Wirth G, Faller JP, Mohseni-Zadeh M, Martinot M, Wainberg MA, Fafi-Kremer S.

J Antimicrob Chemother. 2018 Apr 1;73(4):1045-1053. doi: 10.1093/jac/dkx475.

PMID:
29244129
6.

Cost-effectiveness of public-health policy options in the presence of pretreatment NNRTI drug resistance in sub-Saharan Africa: a modelling study.

Phillips AN, Cambiano V, Nakagawa F, Revill P, Jordan MR, Hallett TB, Doherty M, De Luca A, Lundgren JD, Mhangara M, Apollo T, Mellors J, Nichols B, Parikh U, Pillay D, Rinke de Wit T, Sigaloff K, Havlir D, Kuritzkes DR, Pozniak A, van de Vijver D, Vitoria M, Wainberg MA, Raizes E, Bertagnolio S; Working Group on Modelling Potential Responses to High Levels of Pre-ART Drug Resistance in Sub-Saharan Africa.

Lancet HIV. 2018 Mar;5(3):e146-e154. doi: 10.1016/S2352-3018(17)30190-X. Epub 2017 Nov 22.

7.

Reduced antiretroviral drug efficacy and concentration in HIV-infected microglia contributes to viral persistence in brain.

Asahchop EL, Meziane O, Mamik MK, Chan WF, Branton WG, Resch L, Gill MJ, Haddad E, Guimond JV, Wainberg MA, Baker GB, Cohen EA, Power C.

Retrovirology. 2017 Oct 16;14(1):47. doi: 10.1186/s12977-017-0370-5.

8.

Sophoraflavenone G Restricts Dengue and Zika Virus Infection via RNA Polymerase Interference.

Sze A, Olagnier D, Hadj SB, Han X, Tian XH, Xu HT, Yang L, Shi Q, Wang P, Wainberg MA, Wu JH, Lin R.

Viruses. 2017 Oct 3;9(10). pii: E287. doi: 10.3390/v9100287.

9.

M184I/V substitutions and E138K/M184I/V double substitutions in HIV reverse transcriptase do not significantly affect the antiviral activity of EFdA.

Oliveira M, Brenner BG, Xu H, Ibanescu RI, Mesplède T, Wainberg MA.

J Antimicrob Chemother. 2017 Nov 1;72(11):3008-3011. doi: 10.1093/jac/dkx280.

PMID:
28961903
10.

Investigational HIV integrase inhibitors in phase I and phase II clinical trials.

Han Y, Mesplède T, Wainberg MA.

Expert Opin Investig Drugs. 2017 Nov;26(11):1207-1213. doi: 10.1080/13543784.2017.1378643. Epub 2017 Sep 28. Review.

PMID:
28956664
11.

Antiviral Activity of Bictegravir and Cabotegravir against Integrase Inhibitor-Resistant SIVmac239 and HIV-1.

Hassounah SA, Alikhani A, Oliveira M, Bharaj S, Ibanescu RI, Osman N, Xu HT, Brenner BG, Mesplède T, Wainberg MA.

Antimicrob Agents Chemother. 2017 Nov 22;61(12). pii: e01695-17. doi: 10.1128/AAC.01695-17. Print 2017 Dec.

12.

HIV-1 Resistance to Dolutegravir Is Affected by Cellular Histone Acetyltransferase Activity.

Anstett K, Brenner B, Mesplède T, Wainberg MA.

J Virol. 2017 Oct 13;91(21). pii: e00912-17. doi: 10.1128/JVI.00912-17. Print 2017 Nov 1.

13.

Efficacy, safety, and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort study.

Molina JM, Charreau I, Spire B, Cotte L, Chas J, Capitant C, Tremblay C, Rojas-Castro D, Cua E, Pasquet A, Bernaud C, Pintado C, Delaugerre C, Sagaon-Teyssier L, Mestre SL, Chidiac C, Pialoux G, Ponscarme D, Fonsart J, Thompson D, Wainberg MA, Doré V, Meyer L; ANRS IPERGAY Study Group.

Lancet HIV. 2017 Sep;4(9):e402-e410. doi: 10.1016/S2352-3018(17)30089-9. Epub 2017 Jul 23.

PMID:
28747274
14.

Evaluation of Sofosbuvir (β-D-2'-deoxy-2'-α-fluoro-2'-β-C-methyluridine) as an inhibitor of Dengue virus replication.

Xu HT, Colby-Germinario SP, Hassounah SA, Fogarty C, Osman N, Palanisamy N, Han Y, Oliveira M, Quan Y, Wainberg MA.

Sci Rep. 2017 Jul 24;7(1):6345. doi: 10.1038/s41598-017-06612-2.

15.

Monotherapy with either dolutegravir or raltegravir fails to durably suppress HIV viraemia in humanized mice.

Heredia A, Hassounah S, Medina-Moreno S, Zapata JC, Le NM, Han Y, Foulke JS Jr, Davis C, Bryant J, Redfield RR, Wainberg MA.

J Antimicrob Chemother. 2017 Sep 1;72(9):2570-2573. doi: 10.1093/jac/dkx195.

PMID:
28637235
16.

HIV drug resistance against strand transfer integrase inhibitors.

Anstett K, Brenner B, Mesplede T, Wainberg MA.

Retrovirology. 2017 Jun 5;14(1):36. doi: 10.1186/s12977-017-0360-7. Review.

17.

A Mathematical Model to Predict HIV Virological Failure and Elucidate the Role of Lymph Node Drug Penetration.

Sanche S, Sheehan N, Mesplède T, Wainberg MA, Li J, Nekka F.

CPT Pharmacometrics Syst Pharmacol. 2017 Jul;6(7):469-476. doi: 10.1002/psp4.12200. Epub 2017 May 27.

18.

HIV-1 strains belonging to large phylogenetic clusters show accelerated escape from integrase inhibitors in cell culture compared with viral isolates from singleton/small clusters.

Brenner BG, Ibanescu RI, Oliveira M, Roger M, Hardy I, Routy JP, Kyeyune F, Quiñones-Mateu ME, Wainberg MA; Montreal PHI Cohort Study Group.

J Antimicrob Chemother. 2017 Aug 1;72(8):2171-2183. doi: 10.1093/jac/dkx118.

PMID:
28472323
19.

Development of a DNA vaccine expressing a secreted HIV-1 gp41 ectodomain that includes the membrane-proximal external region.

Melnychuk L, Ajamian L, Jean-Pierre P, Liang J, Gheorghe R, Wainberg MA, Zaharatos GJ.

Vaccine. 2017 May 9;35(20):2736-2744. doi: 10.1016/j.vaccine.2017.03.039. Epub 2017 Apr 6.

PMID:
28392143
20.

The R263K Dolutegravir Resistance-Associated Substitution Progressively Decreases HIV-1 Integration.

Mesplède T, Leng J, Pham HT, Liang J, Quan Y, Han Y, Wainberg MA.

MBio. 2017 Apr 4;8(2). pii: e00157-17. doi: 10.1128/mBio.00157-17.

Supplemental Content

Loading ...
Support Center